About: PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.41 (-4.74%)
PEPG NASDAQ PepGen Ltd
PepGen Ltd share price
Atividade de preço de PEPG
Último preço
$ 2,410
Variação (24h)
-0,12 USD (4,74%)
Volume
766.43K
Volume (média 4 sem.)
-
Abertura
$ 2,54
Variação do dia
$ 2,41 - $ 2,61
Fechamento anterior
$ 2,53
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
PEPG price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals